ONL Therapeutics Overview

  • Founded
  • 2011
Founded
  • Status
  • Private
  • Employees
  • 6
Employees
  • Latest Deal Type
  • Series B
  • Latest Deal Amount
  • $52.5M
Latest Deal Amount
  • Investors
  • 19

ONL Therapeutics General Information

Description

Operator of a clinical-stage biopharmaceutical company committed to protect and improve the vision of patients with a range of retinal diseases and conditions. The company specializes in developing treatments for serious, vision-threatening retinal diseases and conditions with small-molecule peptide for the protection of photoreceptors in retinal detachment, enabling patients to have successful surgeries and improved outcomes.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
  • PO Box 131547
  • Ann Arbor, MI 48113
  • United States
+1 (734) 000-0000

ONL Therapeutics Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

ONL Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Later Stage VC (Series B) 22-Dec-2020 $52.5M 000.00 Completed Generating Revenue
7. Later Stage VC (Series B) 08-Oct-2019 Cancelled Generating Revenue
6. Later Stage VC 25-Apr-2018 00.000 00.000 Completed Generating Revenue
5. Grant 01-Jan-2018 00.000 00.000 Completed Generating Revenue
4. Later Stage VC (Series A) 12-May-2017 00.00 00.000 000.00 Completed Generating Revenue
3. Seed Round 15-Aug-2016 00.000 00.000 00.000 Completed Generating Revenue
2. Grant 01-Sep-2014 $1.37M Completed Generating Revenue
1. Grant 01-Jun-2012 $400K Completed Generating Revenue
To view ONL Therapeutics’s complete valuation and funding history, request access »

ONL Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A 0,000,000 00.000000 00.00 00.00 00 00.00 00.000
Seed 000,000 00.000000 00.00 00.00 00 00.00 00.000
To view ONL Therapeutics’s complete cap table history, request access »

ONL Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Operator of a clinical-stage biopharmaceutical company committed to protect and improve the vision of patients with a ra
Biotechnology
Ann Arbor, MI
6 As of 2021
000.00
00000000000 000.00

000000 0

dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore m
0000 000000000
Cambridge, MA
00 As of 0000
00000
000000000 00000

000000

do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud
0000 000000000
Cincinnati, OH
0 As of 0000
00000
000000&0 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

ONL Therapeutics Competitors (10)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Gemini Therapeutics Venture Capital-Backed Cambridge, MA 00 00000 000000000 00000
000000 Formerly VC-backed Cincinnati, OH 0 00000 000000&0 00000
0000000 Formerly VC-backed Waltham, MA 000 00000 000000 - 000 00000
000000 000 Formerly VC-backed New York, NY 00 00000 000000000 00000
0000000000000 Venture Capital-Backed Charlottesville, VA 0 000.00 0000000000 0 000.00
You’re viewing 5 of 10 competitors. Get the full list »

ONL Therapeutics Executive Team (10)

Name Title Board Seat Contact Info
David Esposito Chief Executive Officer, President & Board Member
Connie Chang Chief Operating Officer
David Zacks MD Co-Founder, Chief Science Officer & Board Member
Andrew Kocab Ph.D Director, Research
Jana Van de Goor Ph.D Vice President, Development
You’re viewing 5 of 10 executive team members. Get the full list »

ONL Therapeutics Board Members (15)

Name Representing Role Since
Cynthia Grosskreutz MD ONL Therapeutics Board Observer 000 0000
David Esposito ONL Therapeutics Chief Executive Officer, President & Board Member 000 0000
David Zacks MD ONL Therapeutics Co-Founder, Chief Science Officer & Board Member 000 0000
Marian Nakada Ph.D Self Board Observer 000 0000
Mark Hooper ONL Therapeutics Chairman 000 0000
You’re viewing 5 of 15 board members. Get the full list »

ONL Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

ONL Therapeutics Investors (19)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Bios Partners Venture Capital Minority 000 0000 000000 0
Exsight Ventures Venture Capital Minority 000 0000 000000 0
InFocus Capital Partners Venture Capital Minority 000 0000 000000 0
Johnson & Johnson Innovation - JJDC Corporate Venture Capital Minority 000 0000 000000 0
Kaitai Capital Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 19 investors. Get the full list »